Literature DB >> 16517807

Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes.

P Wong1, A Robinson, S Shaw, E Rodrigues.   

Abstract

OBJECTIVE: To examine the 21 month clinical outcome and bleeding complications in hospital survivors with non-ST segment elevation acute coronary syndromes (NSTEACS) who were discharged with combined clopidogrel and aspirin anti-thrombotic therapy, and compare with those having ST segment elevation myocardial infarction (STEMI) who were discharged with aspirin alone.
DESIGN: Observational study.
SETTING: A large university hospital. PATIENTS: 224 patients were admitted to hospital with either NSTEACS or STEMI, and survived to discharge between 1 October 2001 and 31 December 2002. MAIN OUTCOME MEASURES: Cardiovascular death, total death, new myocardial infarction, unstable angina requiring hospitalisation, stroke or transient ischaemic attack, coronary revascularisation; and fatal, life threatening, major and minor bleeding over 21 months after discharge.
RESULTS: Despite having no or small infarct (median maximum creatine kinase 155 v 1295 u/l; p<0.001) and taking more antianginal drugs, patients with NSTEACS had similar rates of cardiovascular death (9.5% v 8.3%; p = NS), new myocardial infarction (9.5% v 6.5%; p = NS) or unstable angina requiring hospitalisation (15.5% v 10.2%; p = NS) when compared with STEMI. Fatal, life threatening or major bleeding were <1% in both groups (p = NS); and minor bleeding occurred in 4.3% NSTEACS and 2.8% STEMI patients respectively (p = NS).
CONCLUSIONS: Patients with NSTEACS had a similar and unfavourable long term outcome when compared with STEMI. There was no difference in serious bleeding complications between both groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517807      PMCID: PMC2563701          DOI: 10.1136/pgmj.2005.040097

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  16 in total

Review 1.  Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit.

Authors: 
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

2.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Authors:  Michel E Bertrand; Maarten L Simoons; Keith A A Fox; Lars C Wallentin; Christian W Hamm; Eugene McFadden; Pim J De Feyter; Giuseppe Specchia; Witold Ruzyllo
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

3.  Management of acute coronary syndromes clinical guideline.

Authors: 
Journal:  S Afr Med J       Date:  2001-10

4.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

5.  Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)

Authors:  J Collinson; M D Flather; K A Fox; I Findlay; E Rodrigues; P Dooley; P Ludman; J Adgey; T J Bowker; R Mattu
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

6.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

7.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Authors:  Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Marc J Claeys; Frank Cools; Karen A Hill; Allan M Skene; Carolyn H McCabe; Eugene Braunwald
Journal:  N Engl J Med       Date:  2005-03-09       Impact factor: 91.245

8.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

Authors:  Frans Van de Werf; Diego Ardissino; Amadeo Betriu; Dennis V Cokkinos; Erling Falk; Keith A A Fox; Desmond Julian; Maria Lengyel; Franz-Josef Neumann; Witold Ruzyllo; Christian Thygesen; S Richard Underwood; Alec Vahanian; Freek W A Verheugt; William Wijns
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

9.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

10.  Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.

Authors:  Andrzej Budaj; Salim Yusuf; Shamir R Mehta; Keith A A Fox; Gianni Tognoni; Feng Zhao; Susan Chrolavicius; David Hunt; Matyas Keltai; Maria Grazia Franzosi
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more
  1 in total

1.  Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review.

Authors:  Nafiu Ismail; Kelvin P Jordan; Sunil Rao; Tim Kinnaird; Jessica Potts; Umesh T Kadam; Mamas A Mamas
Journal:  BMJ Open       Date:  2019-02-20       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.